AQUESTIVE THERAPEUTICS INC
NASDAQ: AQST (Aquestive Therapeutics, Inc.)
Kemas kini terakhir: semalam, 1:15AM3.46
-0.25 (-6.61%)
| Penutupan Terdahulu | 3.71 |
| Jumlah Dagangan | 3,360,585 |
| Purata Dagangan (3B) | 2,388,779 |
| Modal Pasaran | 434,879,456 |
| Harga / Jualan (P/S) | 9.58 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2026 |
| Margin Keuntungan | -162.33% |
| Margin Operasi (TTM) | -114.13% |
| EPS Cair (TTM) | -0.650 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -41.00% |
| Nisbah Semasa (MRQ) | 6.12 |
| Aliran Tunai Operasi (OCF TTM) | -39.76 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -22.57 M |
| Pulangan Atas Aset (ROA TTM) | -24.63% |
Sentimen Berita
-
Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks Anifilm ...
06 Nov, 1:05PM
-
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
03 Nov, 3:01PM
AISkor Stockmoo
| Nilai 30% | -1.7 |
| Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Pulangan atas Modal info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | -4.1 |
| Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga turun. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | 0.1 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini bercampur atau neutral. info | |
| Sentimen Pegangan info | NA |
| Wang Pintar 20% | 1.2 |
| Orang dalam membeli bersih baru-baru ini. Harga di bawah harga belian orang dalam. info | |
| Institusi bersih +3.33% daripada saham dalam pemfailan 13F terkini: 95 pemegang menambah, 78 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat +15.1% dari 31 Aug hingga 30 Oct 2026, 13.2 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor mengatasi prestasi pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Perolehan sesaham turun naik. Mencatat kerugian dalam tahun-tahun kebelakangan. info | |
| Di bawah garis aliran jangka sederhana. info | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info | |
| Harga hampir dengan paras sokongan. Paras sokongan dan rintangan menurun. info | |
| Skor Akhir | -1.70 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Aquestive Therapeutics, Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| AQST | 435 M | - | - | - | -1.7 |
| SUPN | 6 B | 27.84% | - | 1.59 | -1.0 |
| ANIP | 2 B | - | 13.74 | 2.57 | -0.1 |
| COLL | 783 M | - | 23.13 | 2.72 | 0.1 |
| TKNO | 480 M | - | - | - | 0.8 |
| TLRY | 279 M | - | - | 0.200 | -2.2 |
|
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.78% |
| % Dimiliki oleh Institusi | 61.11% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bratton Capital Management, L.P. | 30 Sep 2026 | 9,810,958 |
| Samsara Biocapital, Llc | 30 Sep 2026 | 2,434,367 |
| Rosalind Advisors, Inc. | 30 Sep 2026 | 2,000,000 |
| Blue Owl Capital Holdings Lp | 30 Sep 2026 | 1,390,632 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| DALY RICHARD J | 3.52 | - | 28,025 | 98,648 |
| DAVIS MATTHEW W. | - | 3.55 | -12,500 | -44,360 |
| Jumlah Keseluruhan Kuantiti Bersih | 15,525 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 54,288 | |||
| Purata Pembelian Keseluruhan ($) | 3.52 | |||
| Purata Jualan Keseluruhan ($) | 3.55 | |||
| Julat Insider ($) | ||||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| DAVIS MATTHEW W. | Pegawai | 12 Nov 2026 | Jual (-) | 7,197 | 3.57 | 25,693 |
| DAVIS MATTHEW W. | Pegawai | 10 Nov 2026 | Dibuang (-) | 5,303 | 3.52 | 18,667 |
| DALY RICHARD J | Pengarah | 10 Nov 2026 | Beli (+) | 28,025 | 3.52 | 98,648 |
Institusi
Pemilikan institusi: 65.06%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 95 | 11,250,763 |
| Berkurang | 78 | 7,172,973 |
| Baharu | 26 | 2,010,558 |
| Dijual habis | 20 | 1,892,405 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 29,318,686 | 13.2 |
| 15 Oct 2026 | 27,597,742 | 13.9 |
| 30 Sep 2026 | 28,748,212 | 13.1 |
| 15 Sep 2026 | 27,161,738 | 11.8 |
| 31 Aug 2026 | 25,478,782 | 7.2 |
| 14 Aug 2026 | 20,951,747 | 5.2 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference
WARREN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will… |
| 16 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision
Aquestive Therapeutics (NASDAQ:AQST) is preparing for a potential U.S. launch of its needle-free treatment for severe allergic reactions, with an FDA decision expected on March 16, 2027, CEO Dan Barber said at the 2026 Jefferies Global Healthcare Conference. The company’s lead product candidate, An… |
| 09 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will… |
| 06 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks Anifilm ...
Aquestive Therapeutics Inc (AQST) navigates quarterly revenue fluctuations while advancing Anifilm toward a March 2027 FDA decision and securing a $10 million upfront licensing deal for Libervant. |
| 05 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
WARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, today announced that multiple oral and poster… |
| 04 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Aquestive Therapeutics, Inc.'s Q3 2026 earnings call… |
| 04 Nov 2026 | Yahoo Finance |
Aquestive (AQST) Q3 2026 Earnings Call Transcript
Anaphylm's March 2027 FDA date anchors a launch push backed by new funding. |
| 04 Nov 2026 | Yahoo Finance |
What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call
Aquestive Therapeutics (NASDAQ:AQST) said it resubmitted its application for Anaphylm, an epinephrine sublingual film intended for severe allergic reactions, before the end of the third quarter and is preparing for a potential U.S. launch next year if the product receives Food and Drug Administratio… |
| 03 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -30.00% and -31.51%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 03 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics: Q3 Earnings Snapshot
(AP) — Aquestive Therapeutics Inc. (AQST) on Tuesday reported a loss of $16… |
| 03 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approvedCommercial preparations remain on track to support a potential U.S. launch of Anaphylm… |
| 27 Oct 2026 | Yahoo Finance |
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that… |
| 15 Oct 2026 | Yahoo Finance |
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026 WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive… |
| 14 Oct 2026 | Yahoo Finance |
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.Patient market research demonstrated strong preference for buccal film, with 71% of… |
| 29 Sep 2026 | Yahoo Finance |
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc.… |
| 17 Sep 2026 | Yahoo Finance |
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026… |
| 07 Sep 2026 | Yahoo Finance |
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
On August 11, Aquestive Therapeutics (NASDAQ:AQST) reported second-quarter 2026 results and said it remains on track to resubmit its Anaphylm epinephrine film to the FDA in the third quarter of 2026. That single sentence carries the whole story here. A company living and dying by one product… |
| 01 Sep 2026 | Yahoo Finance |
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the… |
| Papar semua | ||
Isyarat Terkini corak lilin dan silang EMA
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |